Cargando…

Integrated mPD‐L1 and metabolic analysis identifies new prognostic subgroups in lung cancers with wild‐type EGFR

Detalles Bibliográficos
Autores principales:	Wang, Guosheng, Hu, Weilei, Chen, Yundi, Wan, Yuan, Li, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684767/ https://www.ncbi.nlm.nih.gov/pubmed/34923764 http://dx.doi.org/10.1002/ctm2.612

Ejemplares similares

Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression
por: Hu, Weilei, et al.
Publicado: (2020)

Mouse Phenome Database (MPD)
por: Bogue, Molly A., et al.
Publicado: (2007)

Mouse Phenome Database (MPD)
por: Maddatu, Terry P., et al.
Publicado: (2012)

MPD: a pathogen genome and metagenome database
por: Zhang, Tingting, et al.
Publicado: (2018)

SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD
por: Gondek, Lukasz P., et al.
Publicado: (2007)

NICA days 2019 and IV MPD Collaboration Meeting
por: Collective
Publicado: (2021)

Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma
por: Hu, Weilei, et al.
Publicado: (2020)

A beam-beam monitoring detector for the MPD experiment at NICA
por: Alvarado, Mauricio, et al.
Publicado: (2018)

MPD: multiplex primer design for next-generation targeted sequencing
por: Wingo, Thomas S., et al.
Publicado: (2017)

Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
por: Zhou, De-Xi, et al.
Publicado: (2022)

mPD-APP: a mobile-enabled plant diseases diagnosis application using convolutional neural network toward the attainment of a food secure world
por: Asani, Emmanuel Oluwatobi, et al.
Publicado: (2023)

Measurement of the neutral and charged K* (892) mesons in the MPD experiment at NICA
por: Ivanishchev, Dmitry, et al.
Publicado: (2019)

Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice
por: Confino, Hila, et al.
Publicado: (2023)

Effect of Sec61 interaction with Mpd1 on endoplasmic reticulum-associated degradation
por: Pereira, Fabio, et al.
Publicado: (2019)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Dominant Distal Myopathy 3 (MPD3) Caused by a Deletion in the HNRNPA1 Gene
por: Hackman, Peter, et al.
Publicado: (2021)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Tang, Yanna, et al.
Publicado: (2015)

Synergy in the Development of Forward Hadron Calorimeters for NA61/SHINE, BM@N, MPD and CBM Experiments
por: Guber, F, et al.
Publicado: (2021)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
por: Oh, Sejin, et al.
Publicado: (2020)

Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression
por: Wang, Min, et al.
Publicado: (2021)

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer
por: Wu, Miaowei, et al.
Publicado: (2020)

Integrated miRNA and mRNA profiling of tumor‐educated macrophages identifies prognostic subgroups in estrogen receptor‐positive breast cancer
por: Bleckmann, Annalen, et al.
Publicado: (2014)

Hypoxia‐related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD‐L1 squamous and adenocarcinoma NSCLC
por: Zhao, Fang, et al.
Publicado: (2021)

In Vitro Metabolic Study of Four Synthetic Cathinones: 4-MPD, 2-NMC, 4F-PHP and bk-EPDP
por: Gavrilović, Ivana, et al.
Publicado: (2022)

The construction of an efficient magnesium–lithium separation thin film composite membrane with dual aqueous-phase monomers (PIP and MPD)
por: Cheng, Xin, et al.
Publicado: (2023)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene
por: Kholod, Olha, et al.
Publicado: (2022)

2-Methyl-2,4-pentanediol (MPD) boosts as detergent-substitute the performance of ß-barrel hybrid catalyst for phenylacetylene polymerization
por: Kinzel, Julia, et al.
Publicado: (2017)

Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1(high) with CD8/PD-1(high)
por: Ma, Si-Rui, et al.
Publicado: (2023)

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization
por: Sun, Yiting, et al.
Publicado: (2022)

Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma
por: Goeppert, Benjamin, et al.
Publicado: (2019)

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer
por: Angell, H. K., et al.
Publicado: (2018)

Design of a Personalized Nasal Device (Matrix-Piston Nasal Device, MPD) for Drug Delivery: a 3D-Printing Application
por: Menegatou, Ioanna-Maria, et al.
Publicado: (2022)

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR
por: Alwithenani, Akram, et al.
Publicado: (2021)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
por: Zheng, Hongmei, et al.
Publicado: (2019)

Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin
por: Qiu, Yajuan, et al.
Publicado: (2019)

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis
por: Lan, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vogbpleisupd56du7s5c65p56q